OR WAIT null SECS
Click here to read the articles and download the PDF
Creating positive experiences and other patient-focused strategies for sponsors to consider when planning and executing cancer studies
Not quite specialty, not quite retail: Cost-effective access and support strategies for a growing, yet underserved, treatment market
The patient-first, pharmacy-first hub model optimizes outcomes and improves care journey for patients with rare disease
May 13, 2022
Company anticipating to double global network size by end of the year
May 12, 2022
Among functions, 80,000 square-foot space will house a 'Center of Excellence'
May 11, 2022
Location will feature aseptic fill-finish technology
May 10, 2022
Deal for PROPENSITY4 grows company’s data analytics knowledge
Pfizer to commercialize NURTEC® ODT, an innovative compound for the prevention and acute treatment of migraine
May 09, 2022
Per supply chain agreement, CDMO will provide analytical product support
May 06, 2022
FDA’s Unapproved Drug Initiative (UDI) is a well-intentioned program in its encouragement of formal FDA review for unapproved legacy medications. But it has inadvertently created financial challenges and access issues, write Steven Lucio and Jenna Stern
May 05, 2022
Among efforts, part of center’s focus revolves providing tools for product commercialization
New partnership focused on improving quality of care, patient outcomes and safety in health systems
May 04, 2022
Facility will feature biologic manufacturing, along with late-stage research and clinical development of cancer medicines